Monsenso AS (MONSO) fair value: what the stock is really worth
We calculate from audited financials what Monsenso AS is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Aug 14, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Monsenso AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range kr 0.1000 – kr 9.11 · fair‑value band kr 0.0255 – kr 0.0510 · the kr 0.2900 price screens above the kr 0.0425 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.
Follow Monsenso AS in your weekly email
Every Wednesday you see whether Monsenso AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark.
Show more
Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark. The company offers Monsenso app for individuals that collects patient-reported and sensor data providing insights into symptoms, adherence, and outcomes. It also provides Monsenso solution, a software as a medical device for mental health professionals application that has data collection, direct messaging, visualization and feedback, psychoeducation and cognitive behavioral therapy, medication reminders, task reminders, consultation prepration, and platform integration that allows monitor patients remotely. In addition, the company offers Monsenso app for carers. Monsenso A/S was incorporated in 2013 and is based in Frederiksberg, Denmark.
Stock analysis
Monsenso AS (MONSO) currently trades at kr 0.2900, while our model-based Fair Value estimate is kr 0.0425, implying the stock looks roughly 582.1% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.0255 (bear) to kr 0.0510 (bull), the price of kr 0.2900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Monsenso AS reported revenue of 8.9M DKK in FY2025 versus 7.1M DKK in FY2021, a compound +5.7%/yr. Reported net income was −7.2M DKK in FY2025.
Key figures
Market cap 19.3M DKK (≈ $2.9M) · P/S ratio 2.25 · EPS (TTM) kr −0.1100 · Net margin −81.0% · Return on equity −68.3% · Return on assets (EBIT) −41.0% · Operating margin −94.0% · Revenue (TTM) 8.9M DKK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 190% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −85%, MONSO screens richer than that median.
Fair Value models
Bear kr 0.0255Fair Value kr 0.0425Bull kr 0.0510
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Start year 2020 (pandemic). Over 10 years: +21.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.8% (2020) → −87.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside−85% · Bottom 25%
Profitability
Return on assets−30% · Bottom 25%
Net margin (TTM)−81% · Bottom 25%
Operating margin (TTM)−94% · Bottom 25%
Growth and dividend
Revenue growth−34% · Bottom 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B0.42× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.33× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 4
FUTURE (revenue growth)0· sector 35
PAST (return on equity)0· sector 5
HEALTH (low debt)88· sector 98
DIVIDEND (yield)0· sector 48
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Monsenso AS Fair Value". https://www.fairvalue-calculator.com/stock/MONSO
Frequently asked questions
Is Monsenso AS (MONSO) overvalued or undervalued?
As of Aug 14, 2026, our model estimates a fair value of kr 0.0425 versus a price of kr 0.2900, about −85% upside (overvalued).
What is the fair value of MONSO?
Our model-based fair value for Monsenso AS is kr 0.0425 (as of Aug 14, 2026), built from audited fundamentals. The current price: kr 0.2900.
What is the quality score of MONSO?
Monsenso AS has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monsenso AS (MONSO)?
Our model-based price target is the fair value of kr 0.0425 (as of Aug 14, 2026) from 1 valuation models. Cautious scenario kr 0.0255, optimistic scenario kr 0.0510. It is a calculation from audited fundamentals, not an analyst target.
What is the Monsenso AS stock forecast for 2026?
Our models put fair value at kr 0.0425, about −85% upside versus a price of kr 0.2900 (overvalued). Cautious scenario kr 0.0255, optimistic scenario kr 0.0510. The calculation is refreshed regularly with new filings.
What is the revenue of Monsenso AS (MONSO)?
Monsenso AS reported trailing-twelve-month revenue of about 8.9M DKK (latest available figure, as of Aug 14, 2026).
What is the intrinsic value of Monsenso AS (MONSO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monsenso AS it is kr 0.0425 per share (as of Aug 14, 2026), against a price of kr 0.2900. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Monsenso AS stock overvalued or undervalued in 2026?
As of Aug 14, 2026, MONSO trades above its calculated fair value: price kr 0.2900, fair value kr 0.0425, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MONSO?
No. The price is what the market pays today (kr 0.2900); the fair value is what the company's own numbers justify (kr 0.0425). For Monsenso AS the two are kr 0.2475 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monsenso AS worth?
The market values Monsenso AS at about 19.3M DKK (market capitalisation, as of Aug 14, 2026). Per share that is kr 0.2900; our models calculate a fair value of kr 0.0425 per share.
What do the bullish and bearish scenarios say about MONSO?
Our models span a range for Monsenso AS: cautious scenario kr 0.0255, base kr 0.0425, optimistic kr 0.0510 per share (as of Aug 14, 2026, price kr 0.2900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monsenso AS (MONSO)?
Balance-sheet figures for Monsenso AS (as of Aug 14, 2026): return on equity −68.3%, debt of 0.24 per unit of equity. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is MONSO from its 52-week high?
Monsenso AS trades at kr 0.2900, about 40% below its 52-week high of kr 0.4840 and 190% above the low of kr 0.1000 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0425 is for.
Which stocks are comparable to Monsenso AS?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monsenso AS stock attractive at the current price?
The data as of Aug 14, 2026: price kr 0.2900, calculated fair value kr 0.0425 (−85%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MONSO calculated?
We run Monsenso AS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0425, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Monsenso AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monsenso AS (MONSO)?
The closing price on Sep 24, 2026 was kr 0.2900. Our model-based fair value is kr 0.0425, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monsenso AS right now?
The price sits above even our optimistic bull case (kr 0.0510). The favourable scenario is already priced in. Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0255 to kr 0.0510) leaves room in how you read the outcome.
Key figures of Monsenso AS
How large is the market capitalisation of Monsenso AS (MONSO)?
The market capitalisation of Monsenso AS is 19.3M DKK (≈ $2.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Monsenso AS (MONSO)?
The price-to-sales ratio of Monsenso AS is 2.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Monsenso AS (MONSO)?
Earnings per share at Monsenso AS are kr −0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Monsenso AS (MONSO)?
The net margin of Monsenso AS is −81.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Monsenso AS (MONSO)?
The return on equity (ROE) of Monsenso AS is −68.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monsenso AS (MONSO)?
On an EBIT basis the return on assets of Monsenso AS is −41.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Monsenso AS (MONSO)?
The operating margin of Monsenso AS is −94.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Monsenso AS (MONSO)?
Revenue at Monsenso AS is growing −33.6% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Monsenso AS (MONSO) generate?
The free cash flow of Monsenso AS is −1.5M DKK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Monsenso AS (MONSO) carry?
The net debt of Monsenso AS is 1.8M DKK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Monsenso AS in the live analysis
One click puts Monsenso AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
